Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with type 2 diabetes mellitus diagnosed for at least 1 year.~* Metformin treatment at a stable dose of at least 1.5 g/day for at least 3 months prior to screening.~Exclusion criteria:~* Age \< legal age of adulthood (18 years).~* Screening HbA1c \<7% or \>10%.~* Screening FPG \>250 mg/dL (\>13.9 mmol/L).~* Pregnancy or lactation, women of childbearing potential with no effective contraceptive method.~* Type 1 diabetes mellitus.~* Treatment with glucose-lowering agent(s) other than metformin in a period of 3 months prior to screening.~* Use of insulin within the last 6 months.~* Previous use of insulin, except for episode(s) of short-term treatment (≤15 consecutive days) due to intercurrent illness.~* Amylase and/or lipase \>3 times the upper limit of the normal laboratory range (ULN) at screening.~* Calcitonin ≥20 pg/ml (5.9 pmol/l) at screening.~* Alanine Transferase (ALT) \>3 ULN at screening.~* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy.~* Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes).~* Uncontrolled or inadequately controlled hypertension at the time of screening with a resting supine systolic or diastolic blood pressure \>180 mmHg or \>110 mmHg, respectively.~* Within the last 6 months prior to screening: history of heart failure requiring hospitalization, myocardial infarction, or stroke. Planned coronary, carotid or peripheral artery revascularisation procedures.~* Body Mass Index (BMI) ≤20 or \>40 kg/m\^2.~* Any previous treatment with lixisenatide~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine/Lixisenatide Fixed Ratio Combination (FRC) (Type: EXPERIMENTAL): FRC injected once daily (QD) for 24 weeks. Dose individually adjusted.
- Insulin glargine (Type: ACTIVE_COMPARATOR): Insulin glargine QD for 24 weeks. Dose individually adjusted.

Based on this trial design, predict the completion outcome and termination type (if applicable).